Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Chronic Diabetic Foot Ulcers Clinical Trial

Official title:

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Phase-III Study to Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04962139
• Other study ID #: ON101CLCT04
• Status: Recruiting
• Phase: Phase 3
• Start date: August 10, 2021
• Est. completion date: August 15, 2023

Study information

• Verified date: July 2022
• Source: Oneness Biotech Co., Ltd.
• Contact: Jessica Ho
• Phone: +886 2 2703 1098
• Email: jessica.ho[@]onenessbio.com.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by the blinded independent evaluator.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 208
• Est. completion date: August 15, 2023
• Est. primary completion date: March 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subjects, male or female, aged 18 to 80 years (inclusive) with Type 1 or Type 2 diabetes undergoing therapy for glycemic control using available diabetes drugs including insulin.

2. Subject has a glycosylated hemoglobin, HbA1c ? 12%.

3. Presence of at least one diabetic foot ulcer that meets all of the following criteria:

1. A full-thickness ulcer of UTWCS Grade I-A or II-A

2. Ulcer size (area) is > 2 cm2 and = 20 cm2 (post-debridement at time of randomization)

3. Ulcer is located on or below the malleoli and present for > 4 weeks (at time of randomization)

4. There is a minimum 3 cm margin between the qualifying Target Ulcer and any other ulcers on the specified foot (post-debridement)

5. No active infection by clinical inspection defined by IDSA/IWGDF criteria Note:

If the subject has more than one qualifying diabetic foot ulcer, the most severe ulcer will be designated as the target ulcer.

4. Subject has adequate vascular perfusion of the affected limb, confirmed by Ankle-Brachial Index (ABI) > 0.8 and < 1.3, and transcutaneous pressure of oxygen (TcPO2) > 30 mmHg on at least one lead.

5. Subject, if female of child-bearing potential, has a negative serum pregnancy test at screening, must not be breastfeeding, and willing to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the study (excluding women who are not of childbearing potential and/or who have been sterilized).

6. Subject should be able to walk and stand on the non-target ulcer limb.

7. Subject is willing to use an off-loading device for the target ulcer on the plantar while ambulation for the duration of the study.

8. Subject / identified caregiver trained on the study procedures is able and willing to comply with study procedures.

9. A signed and dated informed consent form has been obtained from the subject prior to any study-related procedures being performed.

Exclusion Criteria:

1. In response to standard of care, ulcer size reduction is > 30% during the two-week run-in Screening Period (between the first Screening Visit/V0 and Baseline/V2).

2. Ulcers with exposed bone or associated with osteomyelitis. Note: The osteomyelitis should be ruled out by clinical examination (probing of the wound) and X-ray findings.

3. Presence of necrosis, purulence or sinus tracts that cannot be removed by debridement.

4. Body mass index (BMI) > 42 kg/m2

5. Laboratory values at Screening of:

1. White Blood Cells (WBC) < 3.0 X 109 cells/L;> 12.0 X 109 cells/L

2. Liver function studies [Total bilirubin, aspartate aminotransferase (AST) and alanine transaminase (ALT)] > 3x the upper limit of normal

3. Albumin < 2.5 g/dL

4. Renal function studies [Serum Creatinine and Urea] > 3x the upper limit of normal

6. Presence of any clinically significant medical condition(s) in medical history during screening period that, in the opinion of the investigator, could interfere with wound healing, including but not limited to the following:

1. Acute or unstable Charcot foot

2. Current sepsis

3. Active malignant disease. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.

4. Acquired immune deficiency syndrome (AIDS) or HIV positive.

7. Subject is currently receiving (i.e., within 30 days of randomization visit) or scheduled to receive any of following medication or therapies, could interfere with wound healing during the study.

1. immunosuppressants (including chronic systemic corticosteroids)

2. cytotoxic chemotherapy

3. cytostatic therapy

4. autoimmune disease therapy

5. dialysis

6. lower limb revascularization surgery (e.g., angioplasty, artery bypass surgery)

7. growth factors

8. hyperbaric oxygen therapy

9. bioengineered tissue or skin substitutes

10. application of topical steroids to the ulcer surface

11. use of any investigational drug(s)

8. Subjects whose non-target ulcer limb is disabled or amputated above the ankle.

9. Subject's target ulcer is located on the plantar foot with all toes amputated.

10. Subjects who need to stand continuously for more than 4 hours / day and have difficulty complying with off-loading instruction.

11. A psychiatric condition (e.g., suicidal ideation), current or chronic alcohol or drug abuse, determined from the subject's medical history, which, in the opinion of the Investigator, may pose a threat to subject compliance.

12. Has any other factor which may, in the opinion of the investigator, compromise participation and/or follow-up in the study.

Related Conditions & MeSH terms

• Chronic Diabetic Foot Ulcers
• Diabetic Foot
• Foot Ulcer
• Ulcer

Intervention

Drug:
• ON101 Cream
Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica

Other:
• Vehicle Cream
ON101 Cream Placebo

Locations

Country	Name	City	State
United States	Oneness Investigational Site	Carlsbad	California
United States	Oneness Investigational Site	Castro Valley	California
United States	Oneness Investigational Site	Colorado Springs	Colorado
United States	Oneness Investigational Site	Dallas	Texas
United States	Oneness Investigational Site	Fresno	California
United States	Oneness Investigational Site	Houston	Texas
United States	Oneness Investigational Site	Los Angeles	California
United States	Oneness Investigational Site	McAllen	Texas
United States	Oneness Investigational Site	Mesa	Arizona
United States	Oneness Investigational Site	Miami	Florida
United States	Oneness Investigational Site	Miami Lakes	Florida
United States	Oneness Investigational Site	Mount Prospect	Illinois
United States	Oneness Investigational Site	North Miami Beach	Florida
United States	Oneness Investigational Site	O'Fallon	Illinois
United States	Oneness Investigational Site	San Francisco	California
United States	Oneness Investigational Site	Springfield	Illinois
United States	Oneness Investigational Site	Sylmar	California

Sponsors (1)

Lead Sponsor	Collaborator
Oneness Biotech Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The proportion of subjects with complete closure of Target Ulcer	The primary efficacy endpoint for this study is the proportion of subjects with complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by blinded independent evaluators.	20-week Treatment Phase
Secondary	Time to complete closure of Target Ulcer	Time to complete closure of Target Ulcer during the 20-week Treatment Phase, which is assessed by blinded independent evaluators.	20-week Treatment Phase
Secondary	The proportion of patients with Target Ulcer recurrence	The proportion of patients with Target Ulcer recurrence, during the Follow-Up Phase.	12-week Follow-Up Phase